Dossier assessment
Insulin degludec (diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Insulin degludec (diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Insulin degludec (diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Type 2 diabetes mellitus in adults
If treatment with at least 2 blood-glucose lowering drugs (except insulin) is insufficient and if the treatment goal is near-normal blood glucose levels: indication of lesser benefit versus appropriate comparator therapy. Other goals or patients pretreated with insulin: added benefit not proven. No suitable analyses of the DEVOTE study.
Additional information
Federal Joint Committee (G-BA)
2019-07-04 A G-BA decision was published.
Project details
- Project no.
- A18-84
- Commission
- Commission awarded on 29.11.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Insulin degludec - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed